title: Absorption pharmacokinetics of atenolol in patients with the Marfan syndrome.
abstract: The negative inotropic and chronotropic effects of beta-blocker therapy have been reported to reduce morbidity and mortality in patients with Marfan syndrome; however, little is known about the pharmacokinetics of atenolol after oral administration of multiple doses to patients with the Marfan syndrome. We studied the pharmacokinetics of atenolol in 13 such patients aged 18.7 +/- 2.9 years who were receiving 1.78 +/- 0.58 mg/kg/day (70.1 +/- 20.3 mg/m2/day) of atenolol for 6 weeks or longer. Mean +/- SD percentage change in baseline heart rate after the administration of atenolol was -18.03 +/- 16.59% and mean +/- SD percentage change in exercise heart rate after atenolol was -33.22 +/- 14.75% (P < .01). Six to 8 atenolol serum concentrations were collected in each patient during a 12-hour dosing interval and were determined by high-performance liquid chromatography with ultraviolet detection. Serum atenolol concentrations at 0 (123 +/- 70 micrograms/L) and 12 (116 +/- 66 micrograms/L) hours were within 20% of each other and were thus assumed to be at steady-state. A one-compartment, steady-state pharmacokinetic model with first-order absorption and elimination was fitted to the concentration-time data for each patient using nonlinear regression. Maximal concentration was 343 +/- 120 micrograms/L, and the mean half-life was 4.72 hours.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Pharmacy, LeBonheur Children's Medical Center, University of Tennessee, Memphis, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: Phelps
authors.forename: B S
authors.initials: BS
authors.lastname: Alpert
authors.forename: J L
authors.initials: JL
authors.lastname: Ward
authors.forename: J A
authors.initials: JA
authors.lastname: Pieper
authors.forename: J J
authors.initials: JJ
authors.lastname: Lima
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001262:Atenolol / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D004334:Drug Administration Schedule; D005080:Exercise Test; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008382:Marfan Syndrome / Q000378:metabolism* / Q000503:physiopathology; D008657:Metabolic Clearance Rate
chemical_list: D001262:Atenolol